LONDON, September 12, 2013 /PRNewswire/ --
The U.S. equity market ended on a mixed note on Wednesday, September 11, 2013. The S&P 500 and the Dow Jones Industrial Average gained 0.31% and 0.89%, respectively, while the NASDAQ Composite fell by 0.11%. Shares in the biotechnology industry ended lower, even as the broader market finished on a mixed note. The major movers included Gilead Sciences Inc. (NASDAQ: GILD), Halozyme Therapeutics Inc. (NASDAQ: HALO), NPS Pharmaceuticals Inc. (NASDAQ: NPSP), and InterMune Inc. (NASDAQ: ITMN). AAAResearchReports.com free coverage on GILD, HALO, NPSP, and ITMN is available upon registration at:
Shares in Gilead Sciences Inc. ended slightly higher on Wednesday, extending their gains from previous trading sessions. The company's shares ended the day 0.11% higher at $62.93 after oscillating between $62.18 and $63.30. A total of 5.46 million shares were traded, which is below the daily average volume of 8.45 million. The company's stock has rallied 20.00% in the last three months and 6.28% in the last one month, compared to a gain 3.87% and a loss of 0.14% in the S&P 500 during the respective periods. Further, Gilead Sciences Inc.'s stock is trading above its 50-day and 200-day moving averages of $58.82 and $48.77, respectively. Download free technical research on GILD by signing up at:
Halozyme Therapeutics Inc.'s shares fell sharply on Wednesday, even as the broader market ended on a mixed note. The company's shares ended the day at $9.13, which is 1.19% lower than the previous day's price of $9.24. The company's shares fluctuated between $8.90 and $9.32 during the trading session. A total of 1.04 million shares were traded, which is below the daily average volume of 1.55 million. Despite the sharp decline on Wednesday, the company's shares have rallied 37.50% in the last three months and 35.86% in the last one month, outperforming the S&P 500 which has gained 2.05% and lost 0.14% during the respective periods. Moreover, Halozyme Therapeutics Inc.'s stock is trading above its 50-day and 200-day moving averages and close to its 52-week high of $9.45. Register now and get access to free analysis on HALO at:
Shares in NPS Pharmaceuticals Inc. plummeted on Wednesday, even as the broader market finished the day on a mixed note. The company's shares oscillated between $27.94 and $29.33 before finishing the day 4.50% lower at $28.20. A total of 3.31 million shares were traded, which is above the daily average volume of 1.48 million. Despite Wednesday's pullback, NPS Pharmaceuticals Inc.'s shares have rallied 79.85% in the last three months and 24.28% in the last one month, compared with a gain of 3.87% and a loss of 0.14% in the S&P500 during the respective periods. Furthermore, NPS Pharmaceuticals Inc.'s stock is trading above its 50-day and 200-day moving averages as well as close to its 52-week high of $29.53. Sign up and read our complimentary report on NPSP at:
Shares in InterMune Inc. fell sharply on Wednesday ending the day at $14.96, which is 2.67% lower than the previous day's closing price of $15.37. The company's shares oscillated between $14.84 and $15.37 during the trading session. A total of 0.74 million shares were traded, which is below the daily average volume of 1.32 million. InterMune Inc.'s shares have rallied 53.59% in the last three months, outperforming the S&P 500 which has gained 3.87% during the same period. Moreover, InterMune Inc's stock is trading above its 50-day and 200-day moving averages of $13.74 and $10.58, respectively. The free report on ITMN can be downloaded by signing up now at:
- This is not company news. We are an independent source and our views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a best efforts basis and reviewed by an analyst. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
- This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
- If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com.
- For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com.
- Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration.
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider has, through analysts, only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
SOURCE AAA Research Reports